Search results
Results from the WOW.Com Content Network
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs).
Heartburn is a common symptom of late term pregnancy during which up to 80% of pregnant women have experienced it by the end of their third trimester. [12] Heartburn often indicates the development of gastro-esophageal reflux disease (GERD), where the lower esophageal sphincter relaxes due to elevated progesterone levels causing increased ...
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. [6] It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. [7] It is taken by mouth. [7] Common side effects include dizziness and ...
Minor limb malformations seen after valproate exposure. Fetal valproate spectrum disorder (FVSD), previously known as fetal valproate syndrome (FVS), is a rare disease caused by prenatal exposure to valproic acid (VPA), a medication commonly used to treat epilepsy, bipolar disorder, and migraines.
Individuals with heightened exposure to “forever chemicals” early in pregnancy could be at greater risk of weight gain and heart disease later in life, a new study has found. Those with higher ...
A miscarriage, which is also known as an early pregnancy loss, is the unexpected loss of a pregnancy before the 20-week mark, according to the Cleveland Clinic.
This indicated that the virus had to cross the placental barrier to reach the fetus and cause malformations. The time of exposure to the virus also had a direct impact on the incidence of congenital malformations with exposure during week 4, 5–8 and 9–12 weeks of pregnancy caused 61%, 26% and 8% of congenital malformations.